Drug Profile
Bevacizumab biosimilar (Kyomarc) - AbbVie/Amgen
Alternative Names: ABP-215 (Kyomarc); KyomarcLatest Information Update: 12 Jan 2022
Price :
$50
*
At a glance
- Originator Amgen; Watson Pharma
- Developer Allergan; Amgen
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Submission Withdrawal Breast cancer; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cancer
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 27 Mar 2018 Discontinued - Phase-III for Non-small cell lung cancer (Adjunctive treatment, Late-stage disease) in Australia (IV)
- 27 Mar 2018 Discontinued - Phase-III for Non-small cell lung cancer (Adjunctive treatment, Late-stage disease) in USA (IV)